Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1992-02-21
1995-01-31
Righter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A01N 3700, A61K 3119
Patent
active
053859375
ABSTRACT:
Administration of a nitrosating compound, such as nitroglycerin, nitric oxide, S-nitrosothiol, S-nitroso-protein, nitroprusside, sydnonimines, furoxans, nitrosonium salts, and related compounds is used for the treatment or prevention of disease states resulting from hyperhomocysteinemia. The disease states include vascular, ocular, skeletal, neurological, and cytotoxicity disorders. In addition, nitrosating compounds may also be administered for the treatment or prevention of disease states resulting from other sulfur-containing amino acids, such as cysteine.
REFERENCES:
patent: 4778787 (1988-10-01), Catsimpoolas et al.
patent: 5002964 (1991-03-01), Loscalzo
Kang, Soo-Sang, et al., The American Society for Clinical Investigation, Inc., 77:1482-1486, (May 1986).
Aldred et al., J. Chem. Soc. Perking Trans. II: 777-782 (1982).
Brattstrom et al., Atherosclerosis 81:51-60 (1990).
Brattstrom, L. E. et al., Metabolism 34 (11):1073-1077 (1985).
Clarke et al., N. Engl. J. Med. 324:1149-1155 (1991).
Cooke et al., Am. J. Physiol. 28:H804-H812 (1990).
Davis et al., Am. J. Dis. Child 129:1020-1021 (1975).
Gordon et al., Lancet 339:25-26 (1992).
Graeber et al., Pediatr. Res. 16:490-493 (1982).
Grossman et al., Anal. Biochem. 179:28-33 (1989).
Harker et al., J. Clin. Invest. 58:731-741 (1976).
Harker et al., N. Engl. J. Med. 291:537-543 (1974).
Heinecke et al., J. Biol. Chem. 262:10098-10103 (1987).
Henry et al., Br. J. Pharmacol. 98:757-766 (1989).
Ignarro et al., Proc. Natl. Acad. Sci., USA 84:9265-9269 (1987).
Ignarro, Circ. Res. 65:1-21 (1989).
James, J. Am. Coll. Cardiol. 15:763-774 (1990).
Kowaluk et al., J. Pharmacol. Exp. Ther. 255:1256-1264 (1990).
Malinow et al., Circulation 79:1180-1188 (1989).
McCully et al., Res. Comm. Chem. Path. Pharm. 56(3):349-360 (1987).
McCully et al., Am. J. Path. 61(1):1-8 (1970).
McCully, Nature 231:391-92 (1971).
McDonald et al., Lancet 1:745-746 (1964).
Osborne et al., J. Clin. Invest. 83:465-473 (1989).
Palmer et al., Nature 327:524-526 (1987).
Parthasarathy, Biochim. Biophys. Acta 917:337-340 (1987).
Riegel et al., J. Biol. Chem. 112:149-154 (1935).
Root et al., J. Clin. Invest. 55:945-955 (1975).
Skovby, Haemotasis 19 (Supp. 1):4-9 (1989).
Stamler et al., Circ. Res. 65:789-795 (1989).
Stamler et al., Clinical Research 38(2):246A Abstract (1990).
Stamler et al., Am. J. Cardiol. 62:377-380 (1988).
Starkebaum et al., J. Clin. Invest. 77:1370-1376 (1986).
Thomas et al., Thromb Res. 44:859-866 (1986).
Wall et al., Thromb. Res. 18:113-121 (1980).
Zucker et al., Thromb. Haenostas (Stuttgart) 51: 119-124 (1984).
Loscalzo Joseph
Stamler Jonathan
Brigham & Women's Hospital
Cook Rebecca
Herron Charles J.
Olstein Elliot M.
Righter Johann
LandOfFree
Nitrosation of homocysteine as a method for treating homocystein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrosation of homocysteine as a method for treating homocystein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrosation of homocysteine as a method for treating homocystein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1102565